journal article·2025-09Open access

Crystal structure of niraparib tosylate monohydrate Form I, (C 19 H 21 N 4 O)(C 7 H 7 O 3 S)(H 2 O)

James A. Kaduk, Anja Dosen, Tom N. Blanton

Powder Diffraction· Volume 40· Issue 3

Abstract

Abstract The crystal structure of niraparib tosylate monohydrate Form I has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional theory techniques. Niraparib tosylate monohydrate Form I crystallizes in space group P-1 (#2) with a = 7.22060(7), b = 12.76475(20), c = 13.37488(16) Å, α = 88.7536(18), β = 88.0774(10), γ = 82.2609(6)°, V = 1,220.650(16) Å 3 , and Z = 2 at 298 K. The crystal structure consists of alternating double layers of cations and anions (including the water molecules) parallel to the ab -plane. Hydrogen bonds are prominent in the crystal structure. The water molecule acts as a donor to two different O atoms of the tosylate anion and as an acceptor from one of the H of the protonated piperidine ring. The other piperidyl N–H acts as a donor to the carbonyl group of another cation. Surprisingly, there are no cation–anion N–H···O hydrogen bonds. The amide group forms as a N–H···O hydrogen bond to the anion and an intramolecular N–H···N hydrogen bond to the indazole ring. The powder pattern has been submitted to the International Centre for Diffraction Data for inclusion in the Powder Diffraction File™.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: X-ray Diffraction in Crystallography · Crystallography and molecular interactions · Crystal structures of chemical compounds

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Illinois Institute of Technology

North Central College

International Centre for Diffraction Data (ICDD)

Funding

International Centre for Diffraction Data

References (32)

Show source-provided references
1. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
2. 10.1021/ci049780b10.1021/ci049780b ↗
3. 2013
4. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
5. 2024
6. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
7. Putz · 2023
8. 2023
9. 10.3406/bulmi.1907.282010.3406/bulmi.1907.2820 ↗
10. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
11. 10.1017/S088571562400015010.1017/S0885715624000150 ↗
12. 10.1039/D4CE00114A10.1039/D4CE00114A ↗
13. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
14. 10.1107/S002188989800600110.1107/S0021889898006001 ↗
15. Stirk, A. J. , Souza, F. E. S. , Karadeolian, A. , and Rey, A. W. . 2021. “Crystalline Forms of Niraparib Tosylate.” United State Patent Application 2021/0017151 A1.
16. 10.1093/nar/gkac95610.1093/nar/gkac956 ↗
17. Stewart, A. J. , Wang, Y. , Wu, G. , and Yin, J. . 2020. “Crystalline Forms of Niraparib Free Base.” International Patent Application WP2020/072796 A1.
18. 10.1063/1.46788210.1063/1.467882 ↗
19. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
20. 10.1107/S160057752100249610.1107/S1600577521002496 ↗
21. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
22. 10.1021/acs.jctc.2c0095810.1021/acs.jctc.2c00958 ↗
23. 2024
24. 2023
25. Wu, G. , Chaber, J. , McKeown, A. E. , and Foley, J. R. . 2023. “Niraparib Compositions.” U.S. Patent 11673877 B2.
26. Bravais · 1866
27. 10.1002/jcc.2315310.1002/jcc.23153 ↗
28. Kaduk · 2019 · 489
29. 10.1107/S205252061800233010.1107/S2052520618002330 ↗
30. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗
31. A New Law of Crystal Morphology Extending the Law of Bravais
32. 10.1017/S088571561800082910.1017/S0885715618000829 ↗